Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Human Epidermal growth factor Receptor 3 (HER3) is a key member of the EGFR family implicated in cancer progression.
• Despite its known role, no HER3-targeted therapeutics have achieved clinical approval.
• Growing evidence highlights HER3's significance in tumorigenesis and therapeutic resistance.

Purpose of the Study:

• To review the latest advancements in understanding HER3 biology within tumorigenic processes.
• To summarize current and novel strategies for targeting HER3 in cancer treatment.
• To provide an overview of emerging HER3-targeting agents and clinical trials.

Main Methods:

• Literature review of preclinical and clinical studies on HER3.
• Analysis of recent research on HER3 signaling pathways in cancer.
• Synthesis of information on HER3-targeting drug development.

Main Results:

• HER3 plays a crucial role in tumor progression and the development of drug resistance.
• Numerous preclinical and clinical trials are investigating HER3-targeting agents.
• A variety of strategies are being explored to effectively target HER3.

Conclusions:

• Targeting HER3 presents a promising avenue for overcoming cancer progression and drug resistance.
• Further research and clinical trials are essential to develop effective HER3-based therapies.
• Emerging HER3-targeting strategies hold potential for improved cancer treatment outcomes.